Study: NCT03422094

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NeoVax
Description: At each vaccination time point, patients will receive up to 20 synthetic long peptides co-administered with 1.5 mg of poly-ICLC divided into a maximum of four injections (pools). Each pool (of vaccine + poly IC:LC) will be administered to one of the four limbs (right axilla, left axilla, right inguina, left inguina) by subcutaneous injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NeoVax
Description: At each vaccination time point, patients will receive up to 20 synthetic long peptides co-administered with 1.5 mg of poly-ICLC divided into a maximum of four injections (pools). Each pool (of vaccine + poly IC:LC) will be administered to one of the four limbs (right axilla, left axilla, right inguina, left inguina) by subcutaneous injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NeoVax
Description: At each vaccination time point, patients will receive up to 20 synthetic long peptides co-administered with 1.5 mg of poly-ICLC divided into a maximum of four injections (pools). Each pool (of vaccine + poly IC:LC) will be administered to one of the four limbs (right axilla, left axilla, right inguina, left inguina) by subcutaneous injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NeoVax
Description: At each vaccination time point, patients will receive up to 20 synthetic long peptides co-administered with 1.5 mg of poly-ICLC divided into a maximum of four injections (pools). Each pool (of vaccine + poly IC:LC) will be administered to one of the four limbs (right axilla, left axilla, right inguina, left inguina) by subcutaneous injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NeoVax
Description: At each vaccination time point, patients will receive up to 20 synthetic long peptides co-administered with 1.5 mg of poly-ICLC divided into a maximum of four injections (pools). Each pool (of vaccine + poly IC:LC) will be administered to one of the four limbs (right axilla, left axilla, right inguina, left inguina) by subcutaneous injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is a programmed death receptor-1 (PD-1) blocking antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is a programmed death receptor-1 (PD-1) blocking antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is a programmed death receptor-1 (PD-1) blocking antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is a programmed death receptor-1 (PD-1) blocking antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is a programmed death receptor-1 (PD-1) blocking antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab is a recombinant, human monoclonal antibody that binds to the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab is a recombinant, human monoclonal antibody that binds to the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Research blood draw
Description: -Baseline, cycle 2 day 1, cycle 4 day 1, and time of progression or discontinuation of treatment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Research blood draw
Description: -Baseline, cycle 2 day 1, cycle 4 day 1, and time of progression or discontinuation of treatment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Research blood draw
Description: -Baseline, cycle 2 day 1, cycle 4 day 1, and time of progression or discontinuation of treatment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Research blood draw
Description: -Baseline, cycle 2 day 1, cycle 4 day 1, and time of progression or discontinuation of treatment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Research blood draw
Description: -Baseline, cycle 2 day 1, cycle 4 day 1, and time of progression or discontinuation of treatment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis for research
Description: -Baseline, cycle 4 day 1, and time of progression or discontinuation of treatment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis for research
Description: -Baseline, cycle 4 day 1, and time of progression or discontinuation of treatment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis for research
Description: -Baseline, cycle 4 day 1, and time of progression or discontinuation of treatment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis for research
Description: -Baseline, cycle 4 day 1, and time of progression or discontinuation of treatment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis for research
Description: -Baseline, cycle 4 day 1, and time of progression or discontinuation of treatment